Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Veer Bhavnagri Biography and Net Worth

General Counsel of Allogene Therapeutics

Veer Bhavnagri serves as Chief Compliance Officer, General Counsel of the Company. Mr. Bhavnagri also serves as the Company’s Compliance Officer. Prior to joining us, Mr. Bhavnagri served as the Vice President, Corporate Counsel, of Kite from November 2014 until January 2018. Prior to joining Kite, Mr. Bhavnagri was a senior associate at Cooley LLP. Previously, Mr. Bhavnagri was an associate in the New York and Sydney offices of Sullivan & Cromwell LLP. Mr. Bhavnagri received a J.D., magna cum laude, from the University of Michigan Law School. He received an A.B. in mathematical economics and political science, with honors, from Brown University. Mr. Bhavnagri is admitted to practice law in New York and California.

What is Veer Bhavnagri's net worth?: The estimated net worth of Veer Bhavnagri is at least $2.00 million as of February 13th, 2023. Mr. Bhavnagri owns 577,677 shares of Allogene Therapeutics stock worth more than $2,004,539 as of April 20th. This net worth approximation does not reflect any other assets that Mr. Bhavnagri may own. Learn More about Veer Bhavnagri's net worth.
How do I contact Veer Bhavnagri?: The corporate mailing address for Mr. Bhavnagri and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Veer Bhavnagri's contact information.
Has Veer Bhavnagri been buying or selling shares of Allogene Therapeutics?: Veer Bhavnagri has not been actively trading shares of Allogene Therapeutics during the last quarter. Most recently, Veer Bhavnagri sold 3,000 shares of the business's stock in a transaction on Monday, February 13th. The shares were sold at an average price of $6.85, for a transaction totalling $20,550.00. Following the completion of the sale, the general counsel now directly owns 577,677 shares of the company's stock, valued at $3,957,087.45. Learn More on Veer Bhavnagri's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), and Owen Witte (Director). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, Allogene Therapeutics insiders bought shares 1 times. They purchased a total of 190 shares worth more than $684.00. During the last year, insiders at the sold shares 2 times. They sold a total of 28,640 shares worth more than $93,228.00. The most recent insider tranaction occured on January, 30th when CFO Geoffrey M Parker bought 190 shares worth more than $684.00. Insiders at Allogene Therapeutics own 27.4% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 1/30/2024.

Veer Bhavnagri Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2023	Sell	3,000	$6.85	$20,550.00	577,677
1/17/2023	Sell	3,000	$7.04	$21,120.00	580,677
12/15/2022	Sell	5,602	$7.53	$42,183.06	583,677
3/15/2022	Sell	8,849	$7.68	$67,960.32
8/16/2021	Sell	5,000	$21.00	$105,000.00
7/15/2021	Sell	5,000	$21.55	$107,750.00	426,353
5/18/2021	Sell	5,000	$30.00	$150,000.00	426,353
4/15/2021	Sell	10,000	$32.05	$320,500.00	431,353
10/6/2020	Sell	10,000	$40.00	$400,000.00	363,902
10/1/2020	Sell	25,000	$36.52	$913,000.00	378,902
8/3/2020	Sell	31,553	$36.89	$1,163,990.17	385,455

Veer Bhavnagri Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $3.47

$3.38

$3.56

50 Day Range

MA: $4.49

$3.46

$5.63

2 Week Range

Now: $3.47

$2.23

$6.89

Volume

2,013,218 shs

Average Volume

1,533,953 shs

Market Capitalization

$586.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad